Loading...
At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2014), held May 30 through June 3 in Chicago, specialists discussed the latest cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to cover key presentations at the conference. Here, Michael E. Williams, MD, ScM, reviews new findings in malignant hematology.
Cavalli and colleagues conducted a multicenter, randomized, phase III trial (abstract 8500) involving 487
newly diagnosed mantle cell lymphoma patients ineligible for bone-marrow transplant to test the substitution of bortezomib (an active single agent in the relapsed setting) for vincristine in the standard R-CHOP-21 regimen (ri…